← All trials
NCT06011486
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2023
- Primary completion
- Jun 10, 2024
- Completion date
- Jun 10, 2026
- First posted
- Aug 25, 2023
- Last posted
- Aug 25, 2023
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Albert Einstein Israelite HospitalLead sponsor
- Albert Einstein Israelite HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.